NWBO · Northwest Biotherapeutics Inc · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Because of recurring operating losses and operating cash flow deficits, there is substantial doubt about the Company’s ability to continue as a going concern for at least one year from the date of this filing. The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, however, they do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 | FY2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.17M | $1.38M | $1.38M | $1.93M | $1.68M | $1.01M | $1.29M | $2.41M | $412K | $336K | $623K | $1.74M | $1.45M | $809K | $772K | $10K | $10K | — | — | — | — | — | — | — | — | — | |
| $0 | — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| $672K | — | — | — | — | — | — | — | — | — | — | — | — | $809K | $772K | $10K | $10K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | 100% | 100% | 100% | 100% | — | — | — | — | — | — | — | — | — | |
| $23.57M | $28.79M | $34.89M | $27.73M | $35.51M | $20.31M | $33.64M | $14.11M | $18.15M | $33.52M | $60.08M | $103.12M | $85.64M | $43.91M | $28.91M | $13.45M | $9.9M | — | — | — | — | — | — | — | — | — | |
| $28.94M | $32.51M | $33M | $29.71M | $33.35M | $33.4M | $54.26M | $16.28M | $22.51M | $12.46M | $10.87M | $18.33M | $16.96M | $12.38M | $15.68M | $13.34M | $5.46M | — | — | — | — | — | — | — | — | — | |
| $2.67M | $2.06M | $1.74M | $1.53M | $1.25M | $324K | $87K | $21K | $1.29M | $439K | $189K | $56K | $11K | $11K | $14K | $10K | $2000 | — | — | — | — | — | — | — | — | — | |
| -$50.33M | -$59.91M | -$66.51M | -$55.51M | -$67.18M | -$52.7M | -$86.61M | -$27.98M | -$41.48M | -$54.68M | -$79.27M | -$126.28M | -$101.14M | -$55.47M | -$43.83M | -$26.79M | -$15.35M | — | — | — | — | — | — | — | — | — | |
| — | -4347.9% | -4812.45% | -2873.08% | -3991.74% | -5243.98% | -6708.37% | -1160.95% | -10068.2% | -16273.21% | -12723.27% | -7261.87% | -6956.19% | -6857.11% | -5676.81% | -267870% | -153540% | — | — | — | — | — | — | — | — | — | |
| -$47.66M | -$57.85M | -$64.76M | -$53.98M | -$65.93M | -$52.38M | -$86.52M | -$27.96M | -$40.19M | -$54.24M | -$79.08M | -$126.23M | -$101.13M | -$55.46M | -$43.81M | -$26.78M | -$15.35M | — | — | — | — | — | — | — | — | — | |
| $9.42M | $8.7M | $7.77M | $5.24M | $6.07M | $5.01M | $8.54M | $2.98M | $9.87M | $5.55M | $3.82M | $4.15M | $996K | $842K | $13.44M | $7.65M | $7.88M | — | — | — | — | — | — | — | — | — | |
| $12.06M | -$785K | -$17.27M | -$7.09M | -$37.85M | $231.83M | -$443.22M | $7.17M | $5.69M | -$18.47M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$60.7M | -$83.78M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$537K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | |
| -$37.73M | -$60.16M | -$83.78M | -$62.6M | -$105.03M | $179.13M | -$529.82M | -$20.81M | -$35.79M | -$73.14M | -$80.21M | -$114.74M | -$135.63M | -$65.79M | -$67.32M | -$32.83M | -$27.37M | -$26.95M | -$22.33M | -$21.25M | -$1.4M | -$9.94M | -$8.51M | -$5.75M | -$12.8M | -$10.94M | |
| — | -4365.89% | -6062.08% | -3240.11% | -6240.76% | 17823.48% | -41039.58% | -863.57% | -8687.86% | -21768.75% | -12875.44% | -6598.1% | -9328.34% | -8132.14% | -8720.21% | -328300% | -273680% | — | — | — | — | — | — | — | — | — | |
| -$38.88M | -$61.48M | -$85.19M | -$64.37M | -$105.03M | $179.13M | -$529.82M | -$20.81M | -$53.56M | -$74.41M | -$85.86M | -$114.74M | — | -$65.79M | -$67.32M | -$32.83M | -$27.37M | — | — | — | — | — | — | — | — | — | |
| -$37.28M | -$65.45M | -$83.69M | -$65.98M | -$102.24M | $180.63M | -$531.81M | -$20.98M | -$34.2M | -$75.59M | -$78.24M | -$114.67M | -$135.63M | -$65.98M | — | -$32.83M | -$27.47M | -$26.98M | -$22.35M | -$21.25M | — | — | — | — | — | — | |
| USD/shares | -$0.03 | -$0.04 | -$0.07 | -$0.06 | -$0.10 | $0.21 | -$0.73 | -$0.04 | — | — | — | — | — | — | — | -$0.35 | -$0.41 | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.03 | -$0.04 | -$0.07 | -$0.06 | -$0.10 | -$0.06 | -$0.73 | -$0.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 1.46B | 1.24B | 1.12M | 1.02M | 873.52K | 725.13K | 564.19K | 440.02M | 242.85M | 111.08M | 77.71M | 59.25M | 32.87M | 11.76K | 94.2M | 67.06M | — | — | — | — | — | — | — | — | — |
| shares | — | 1.46B | 1.24B | 1.12M | 1.02M | 1.01M | 725.13K | 564.19K | 440.02M | 242.85M | 111.08M | 77.71M | 59.25M | 32.87M | 11.76K | 5887 | — | — | — | — | — | — | — | — | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2013–FY2015: $240K in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Long-term debt, including current maturities | 2026-06-30 | USD 51,973,000 | 10-Q filed 2026-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Operating lease liabilities | 2026-06-30 | USD 4,468,000 | 10-Q filed 2026-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 317 similar-size Biotechnology companies (of 531 listed).